Zeiss Vision expands its lab capabilities

Article

Carl Zeiss Vision (CZV) and US Optical of East Syracuse, NY, have signed a partnership agreement to manufacture Zeiss Individual and other CZV custom lenses on-site using the proprietary Zeiss PreciseForm process.

Key Points

San Diego-Carl Zeiss Vision (CZV) and US Optical of East Syracuse, NY, have signed a partnership agreement to manufacture Zeiss Individual and other CZV custom lenses on-site using the proprietary Zeiss PreciseForm process.

"US Optical is one of the most innovative labs in the country and has been a leader in free-form manufacturing since its inception," said Fred Howard, president, Americas-Pacific, CZV. "They are already a great partner for premium ZEISS traditional progressives and AR. The lab is the natural choice to become our latest partner for personalized lenses, and we are very pleased to extend our relationship with them."

US Optical has begun the extensive certification procedure for the proprietary Zeiss PreciseForm manufacturing process. When certification is complete later this year, the company will manufacture the full line of CZV customized, free-form progressive lenses.

Also, CZV–Florida, formerly Tri-City Optical, has begun manufacturing Zeiss Individual and other customized lenses in its recently remodeled facility.

The lab underwent the qualification process to meet the standards of PreciseForm manufacturing, which included the installation of free-form generators, ZEISS coating equipment, and robotic finishing equipment.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Priya S. Vakharia, MD; and Deepak Sambhara, MD, FASRS, provide tips to ensure effective comanagement between retina specialists, optometrists, and ophthalmologists.
Presenters from the Collaborative Care Symposium 2025 give their key takeaways from their presentations.
Erin Tomiyama, OD, PhD, FAAO, offers actionable advice for myopia management and perspective for practitioners ready to refine their approach.
Extended lotilaner 0.25% therapy shows meibomian gland benefits
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Lori Wright, JD, sat down to talk about a presentation at Collaborative Care Symposium about the risk under federal statutes and how to minimize that risk as an optometrist or an ophthalmic practice.
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Mark Bullimore, MCOptom, PhD, details the importance of preparing optometric students for myopic patient care in a Collaborative Care Symposium (CCS) 2025 presentation.
© 2025 MJH Life Sciences

All rights reserved.